BUTAPHOS INJECTION

Mechanism of action

Cyanocobalamin serves as a cofactor for methionine synthase and L-methylmalonyl-CoA mutase enzymes. Methionine synthase is essential for the synthesis of purines and pyrimidines that form DNA. L-methylmalonyl-CoA mutase is involved in the degradation of propionate, crucial for fat and protein metabolism. The lack of vitamin B12 results in the accumulation of methylmalonyl CoA, contributing to neurological manifestations. Additionally, it is vital for the synthesis of methionine from homocysteine, and its deficiency can lead to functional folate deficiency, which impacts red blood cell formation.

Pharmacodynamics

Cyanocobalamin corrects vitamin B12 deficiency and alleviates symptoms and laboratory abnormalities associated with pernicious anemia, such as megaloblastic indices, gastrointestinal lesions, and neurological damage. It is essential for growth, cell reproduction, hematopoiesis, nucleoprotein, and myelin synthesis. The drug significantly impacts fat and carbohydrate metabolism, as well as protein synthesis. Rapidly dividing cells, such as those in the bone marrow, have a high demand for vitamin B12. Parenteral administration of cyanocobalamin can quickly reverse the anemia and gastrointestinal symptoms of vitamin B12 deficiency, while also preventing the progression of related neurological damage.

Pharmacokinetics

Cyanocobalamin is absorbed in the intestine, primarily in the ileum, via specific transport mechanisms that may be impaired in individuals with intrinsic factor deficiency (as seen in pernicious anemia). Once absorbed, it is widely distributed in body tissues, with significant concentrations found in the liver, kidneys, and heart. The vitamin is stored in the liver, where it can be released into circulation as needed. Cyanocobalamin undergoes conversion to its active forms, methylcobalamin and adenosylcobalamin, which are utilized in various metabolic processes. The elimination half-life is variable, but it is generally excreted via urine as metabolites

Adverse effects

• Abdominal distension
• Decreased appetite
• Flatulence
• Nausea

Interactions

• Folic acid may interact with cyanocobalamin, especially in cases of megaloblastic anemia caused by folate deficiency.

Precautions

• Should not be given alone for pernicious anemia.
• Use caution in patients with Leber's disease, as it may worsen optic atrophy.

Pregnancy

Cyanocobalamin is essential during pregnancy as it helps prevent neural tube defects. It is advised that females of childbearing potential take 5 mg of folic acid daily before conception and throughout pregnancy.

Breast-feeding

Cyanocobalamin is generally considered safe during breastfeeding, but it is advised to monitor the infant for any adverse effects.

Storage

Store in a cool, dry place, away from direct sunlight. Protect from moisture.

Formulations

• Tablet: 1000 micrograms
• Tablet: 500 micrograms
• Tablet: 100 micrograms
• Oral solution: 50 micrograms per ml
• Solution for injection: 1000 micrograms per ml

Indications

• Appetite stimulation
• Metabolic enhancement in animals
• Support in conditions of poor appetite

Dosage

Children: Refer to specific veterinary dosing guidelines, as human use is not well established.

Adults: Refer to specific veterinary dosing guidelines, as human use is not well established.

Mechanism of action

Butaphosphan is believed to enhance the bioavailability of phosphorus in the body, which plays a critical role in various metabolic pathways, including the synthesis of ATP, nucleic acids, and phospholipids. It may also stimulate the release of insulin, promoting glucose utilization and energy production.

Pharmacodynamics

Butaphosphan acts primarily as a metabolic enhancer, improving appetite and energy levels. It contributes to nutritional support by facilitating the metabolism of carbohydrates and fats. The pharmacological effects are generally observed in the gastrointestinal and metabolic systems, leading to improved overall health and vitality.

Pharmacokinetics

The pharmacokinetics of butaphosphan are not extensively studied, but it is expected to be rapidly absorbed after administration, with effects seen shortly thereafter. Metabolism occurs primarily in the liver, and excretion is likely through the kidneys. The specific half-life and elimination pathways are not well documented.

Pregnancy

There is limited data on the use of butaphosphan in pregnancy. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether butaphosphan is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Formulations

• Injectable solution

Indications

• Antimicrobial therapy
• Neurological disorders
• Cancer treatment
• Metabolic disorders

Dosage

Children: Refer to specific product guidelines or clinical protocols for paediatric dosing recommendations.

Adults: Refer to specific product guidelines or clinical protocols for adult dosing recommendations.

Mechanism of action

Phosphonous compounds generally act by inhibiting key enzymes in metabolic pathways, particularly those involved in nucleotide synthesis and energy metabolism. This inhibition can lead to altered cellular function and may promote apoptosis in certain cell types. Specific phosphonous derivatives may also exhibit actions on neurotransmitter systems, impacting synaptic transmission.

Pharmacodynamics

The pharmacodynamics of phosphonous compounds are influenced by their ability to interact with biological targets, leading to changes in cellular signaling pathways. These interactions can result in modulation of enzyme activity, alterations in gene expression, and effects on cell proliferation. The therapeutic effects are often dose-dependent, and the compounds may exhibit synergistic effects when used in combination with other agents.

Pharmacokinetics

Phosphonous compounds typically exhibit variable absorption, distribution, metabolism, and excretion profiles depending on their chemical structure. Many are well-absorbed following oral administration, with peak plasma concentrations occurring within a few hours. They may be extensively metabolized in the liver, leading to various metabolites that can contribute to therapeutic effects or toxicity. Renal excretion is a common pathway for elimination, though some compounds may undergo biliary excretion.

Pregnancy

Phosphonous compounds should be used with caution during pregnancy; potential risks should be evaluated against benefits.

Breast-feeding

The safety of phosphonous compounds during breastfeeding is not well established; caution is advised.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Mechanism of action

Vitamin B12 serves as a cofactor for _methionine synthase_ and _L-methylmalonyl-CoA mutase_ enzymes. Methionine synthase is essential for the synthesis of purines and pyrimidines that form DNA. L-methylmalonyl-CoA mutase converts L-methylmalonyl-CoA to _succinyl-CoA_ in the degradation of propionate, an important reaction required for both fat and protein metabolism. It is a lack of vitamin B12 cofactor in the above reaction and the resulting accumulation of methylmalonyl CoA that is believed to be responsible for the neurological manifestations of B12 deficiency. Succinyl-CoA is also necessary for the synthesis of hemoglobin. In tissues, vitamin B12 is required for the synthesis of _methionine_ from homocysteine. Methionine is required for the formation of S-adenosylmethionine, a methyl donor for nearly 100 substrates, comprised of DNA, RNA, hormones, proteins, as well as lipids. Without vitamin B12, tetrahydrofolate cannot be regenerated from 5-methyltetrahydrofolate, and this can lead to functional folate deficiency,. This reaction is dependent on methylcobalamin (vitamin B12) as a co-factor and is also dependent on folate, in which the methyl group of methyltetrahydrofolate is transferred to homocysteine to form _methionine_ and _tetrahydrofolate_. Vitamin B12 incorporates into circulating folic acid into growing red blood cells; retaining the folate in these cells. A deficiency of vitamin B12 and the interruption of this reaction leads to the development of megaloblastic anemia.

Pharmacodynamics

**General effects** Cyanocobalamin corrects vitamin B12 deficiency and improves the symptoms and laboratory abnormalities associated with pernicious anemia (megaloblastic indices, gastrointestinal lesions, and neurologic damage). This drug aids in growth, cell reproduction, hematopoiesis, nucleoprotein, and myelin synthesis. It also plays an important role in fat metabolism, carbohydrate metabolism, as well as protein synthesis. Cells that undergo rapid division (for example, epithelial cells, bone marrow, and myeloid cells) have a high demand for vitamin B12. **Parenteral cyanocobalamin effects** The parenteral administration of vitamin B12 rapidly and completely reverses the megaloblastic anemia and gastrointestinal symptoms of vitamin B12 deficiency. Rapid parenteral administration of vitamin B12 in deficiency related neurological damage prevents the progression of this condition. **Nasal spray effects** In 24 vitamin B12 deficient patients who were already stabilized on intramuscular (IM) vitamin B12 therapy, single daily doses of intranasal cyanocobalamin for 8 weeks lead to serum vitamin B12 concentrations that were within the target therapeutic range (>200 ng/L).